Stockscreener 앱 받기
5.77
7.05%
0.38
시간 외 거래:
5.77
전일 마감가:
$5.39
열려 있는:
$5.44
하루 거래량:
110.32K
Relative Volume:
0.95
시가총액:
$326.18M
수익:
$34.16M
순이익/손실:
$-98.43M
주가수익비율:
-2.4658
EPS:
-2.34
순현금흐름:
$-119.33M
1주 성능:
+14.03%
1개월 성능:
+15.40%
6개월 성능:
+23.55%
1년 성능:
-28.59%
1일 변동 폭
$5.30
$5.78
1주일 범위
$4.98
$5.78
52주 변동 폭
$2.9448
$10.25
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
명칭
Foghorn Therapeutics Inc
전화
617-586-3100
주소
500 TECHNOLOGY SQUARE, CAMBRIDGE
FHTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
5.77 | 304.70M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-23 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-01-30 | 개시 | B. Riley Securities | Buy |
| 2024-09-03 | 개시 | Jefferies | Buy |
| 2024-08-19 | 개시 | Evercore ISI | Outperform |
| 2023-03-28 | 개시 | BofA Securities | Buy |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-22 | 개시 | H.C. Wainwright | Buy |
| 2020-11-17 | 개시 | Cowen | Outperform |
| 2020-11-17 | 개시 | Goldman | Buy |
| 2020-11-17 | 개시 | Morgan Stanley | Overweight |
| 2020-11-17 | 개시 | Wedbush | Outperform |
모두보기
Foghorn Therapeutics Inc 주식(FHTX)의 최신 뉴스
Can Foghorn Therapeutics Inc. stock double in the next year2025 Key Highlights & Real-Time Volume Analysis Alerts - خودرو بانک
Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why - MSN
Trend analysis for Foghorn Therapeutics Inc. this weekQuarterly Profit Review & Community Verified Watchlist Alerts - Newser
What’s the analyst consensus on Foghorn Therapeutics Inc.2025 Volume Leaders & Technical Buy Zone Confirmation - خودرو بانک
Has Foghorn Therapeutics Inc. found a price floorJuly 2025 Highlights & Risk Managed Investment Strategies - Newser
Backtesting results for Foghorn Therapeutics Inc. trading strategies2025 Key Lessons & Weekly Breakout Stock Alerts - Newser
Will earnings trigger a reversal in Foghorn Therapeutics Inc.Earnings Overview Summary & Community Consensus Picks - Newser
Using RSI to spot recovery in Foghorn Therapeutics Inc.July 2025 Weekly Recap & Safe Swing Trade Setups - Newser
How cyclical is Foghorn Therapeutics Inc.’s revenue streamTrade Performance Summary & Low Risk High Win Rate Picks - خودرو بانک
Leading vs lagging indicators on Foghorn Therapeutics Inc. performanceTrade Ideas & Risk Controlled Swing Trade Alerts - Newser
Does Foghorn Therapeutics Inc. have high return on assetsJuly 2025 Movers & AI Enhanced Execution Alerts - خودرو بانک
Is Foghorn Therapeutics Inc. a speculative investmentEarnings Recap Summary & Weekly High Potential Stock Alerts - خودرو بانک
Is Foghorn Therapeutics Inc. trending in predictive chart modelsMarket Performance Recap & AI Optimized Trading Strategy Guides - Newser
How to build a custom watchlist for Foghorn Therapeutics Inc.2025 Big Picture & High Conviction Buy Zone Picks - Newser
Foghorn Therapeutics Inc. stock prediction for this weekAnalyst Downgrade & Smart Allocation Stock Tips - Newser
What the charts say about Foghorn Therapeutics Inc. todayExit Point & Reliable Price Breakout Alerts - Newser
Value Recap: Does Foghorn Therapeutics Inc. stock benefit from AI growthJuly 2025 Momentum & Weekly Watchlist for Consistent Profits - خودرو بانک
Price action breakdown for Foghorn Therapeutics Inc.July 2025 Breakouts & Technical Buy Zone Confirmations - Newser
Does Foghorn Therapeutics Inc. stock benefit from AI growth2025 Trade Ideas & Weekly Market Pulse Updates - خودرو بانک
How did FHTX's Q4 2024 earnings surprise impact investor confidence? - AInvest
What earnings revisions data tells us about Foghorn Therapeutics IncEarnings Risk Report & AI Forecast Swing Trade Picks - Newser
What earnings revisions data tells us about Foghorn Therapeutics Inc.Weekly Trend Report & Proven Capital Preservation Tips - Newser
AI Indicators Detect Buy Opportunity in Foghorn Therapeutics Inc.July 2025 Movers & Technical Confirmation Alerts - beatles.ru
Combining price and volume data for Foghorn Therapeutics Inc.Market Performance Summary & Precise Swing Trade Alerts - Newser
Heatmap analysis for Foghorn Therapeutics Inc. and competitors2025 Market Overview & Free Accurate Trade Setup Notifications - Newser
Foghorn Therapeutics Advances in Precision Therapeutics - TipRanks
Is Foghorn Therapeutics Inc. a good ESG investmentJuly 2025 Price Swings & Low Drawdown Trading Strategies - خودرو بانک
Uveal Melanoma Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Novartis, Foghorn Therapeutics Inc., TriSalus Life Sciences, Inc., AstraZeneca - The Globe and Mail
Does Foghorn Therapeutics Inc. have pricing powerLayoff News & Technical Buy Zone Confirmation - خودرو بانک
How to track smart money flows in Foghorn Therapeutics Inc.Weekly Investment Recap & Free Growth Oriented Trading Recommendations - Newser
Foghorn Therapeutics Inc. stock trend forecastPortfolio Value Report & Safe Entry Momentum Tips - Newser
Raymond James Financial Inc. Has $8.10 Million Stake in Foghorn Therapeutics Inc. $FHTX - Defense World
Wellington Management Group LLP Grows Position in Foghorn Therapeutics Inc. $FHTX - Defense World
When is the best time to exit Foghorn Therapeutics Inc.July 2025 Volume & Fast Exit and Entry Strategy Plans - Newser
Aug Big Picture: Is Foghorn Therapeutics Inc. a speculative investmentWeekly Stock Recap & AI Driven Stock Movement Reports - خودرو بانک
Is Foghorn Therapeutics Inc. vulnerable to short sellers2025 Price Momentum & Stepwise Entry/Exit Trade Alerts - خودرو بانک
Can Foghorn Therapeutics Inc. expand into new marketsJuly 2025 Rallies & AI Enhanced Execution Alerts - خودرو بانک
Ranking Foghorn Therapeutics Inc. among high performing stocks via toolsJuly 2025 Catalysts & Weekly Momentum Picks - Newser
Wall Street Analysts Predict a 130.63% Upside in Foghorn Therapeutics (FHTX): Here's What You Should Know - Yahoo Finance
Real time social sentiment graph for Foghorn Therapeutics Inc.Earnings Summary Report & High Yield Equity Trading Tips - Newser
Predicting Foghorn Therapeutics Inc. trend using moving averages2025 Sector Review & Proven Capital Preservation Methods - Newser
How sentiment analysis helps forecast Foghorn Therapeutics Inc.July 2025 Spike Watch & Community Consensus Trade Signals - Newser
Does Foghorn Therapeutics Inc. fit your quant trading modelRate Cut & Weekly High Potential Stock Alerts - Newser
Foghorn Therapeutics Inc. stock outlook for YEARQuarterly Profit Report & Reliable Trade Execution Plans - Newser
Foghorn Therapeutics Inc (FHTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Foghorn Therapeutics Inc 주식 (FHTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Costa Carlos | Chief People Officer |
Sep 23 '24 |
Option Exercise |
3.72 |
857 |
3,188 |
857 |
| Costa Carlos | Chief People Officer |
Sep 20 '24 |
Sale |
10.04 |
35,756 |
358,990 |
0 |
| Costa Carlos | Chief People Officer |
Sep 23 '24 |
Sale |
10.17 |
857 |
8,716 |
0 |
| Costa Carlos | Chief People Officer |
Sep 18 '24 |
Option Exercise |
3.72 |
11,574 |
43,055 |
11,574 |
| Costa Carlos | Chief People Officer |
Sep 18 '24 |
Sale |
10.05 |
11,574 |
116,319 |
0 |
| Costa Carlos | Chief People Officer |
Sep 17 '24 |
Option Exercise |
3.72 |
10,272 |
38,212 |
10,272 |
| Costa Carlos | Chief People Officer |
Sep 16 '24 |
Option Exercise |
3.72 |
400 |
1,488 |
400 |
| Costa Carlos | Chief People Officer |
Sep 17 '24 |
Sale |
10.04 |
10,272 |
103,131 |
0 |
| Costa Carlos | Chief People Officer |
Sep 16 '24 |
Sale |
10.00 |
400 |
4,000 |
0 |
1.40%
자본화:
|
볼륨(24시간):